Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Session 2 - CDK4-6 inhibitors in advanced breast cancer

CDK4-6 inhibition in patients with metastatic HR positive / HER2 negative breast cancer: Benefit in endocrine resistant disease


20 May 2023


Session 2 - CDK4-6 inhibitors in advanced breast cancer


Targeted Therapy

Tumour Site

Breast Cancer


A. Marra, IT


This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.